FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Timothy Hughes

Research Profile

Disorders

Chemicals & Drugs

Physiology

Drug Resistance, Neoplasm

Concepts & Ideas

Procedures

Anatomy

Co-author Network

Publications

TOP 3
Deborah L White; V A Saunders; L N Eadie; D K Hiwase; Timothy P Hughes
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.
Daniel Thomas; Andrew H Wei; Joanna Woodcock; Andrew C W Zannettino; Emma F Barry; Paul G Ekert; Stephen Fitter; Benjamin D Green; Timothy P Hughes; Angel F Lopez; Yuefang Ma; Stuart M Pitson; Jason A Powell; Peter R Shepherd; Mark A Guthridge
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
D B Watkins; Deborah L White; Timothy P Hughes; R J D'Andrea
NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Timothy Hughes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Deborah L White; V A Saunders; L N Eadie; D K Hiwase; Timothy P Hughes
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.
Leukemia 2013;27(5):1201-4.
2013: Daniel Thomas; Andrew H Wei; Joanna Woodcock; Andrew C W Zannettino; Emma F Barry; Paul G Ekert; Stephen Fitter; Benjamin D Green; Timothy P Hughes; Angel F Lopez; Yuefang Ma; Stuart M Pitson; Jason A Powell; Peter R Shepherd; Mark A Guthridge
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
PLoS biology 2013;11(3):e1001515.
2013: D B Watkins; Deborah L White; Timothy P Hughes; R J D'Andrea
NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis.
Leukemia 2013;27(2):489-90.
2013: Kate Vandyke; David T Yeung; Jenny Drew; Stephen Fitter; Seiji Fukumoto; Timothy P Hughes; Christopher G Schultz; Natalie Sims; Andrew C W Zannettino
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.
The Journal of clinical endocrinology and metabolism 2013;98(1):67-76.
2012: françois guilhot; Michael Hayes; Timothy P Hughes; Michele Baccarani; Jorge Cortes; Brian J Druker; Insa Gathmann; Camille Granvil; Yanfeng Wang
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Haematologica 2012;97(5):731-8.
2012: David T Yeung; Timothy P Hughes
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.
Critical reviews in oncogenesis 2012;17(1):17-30.
2011: Susan Branford; Timothy P Hughes
Mutational analysis in chronic myeloid leukemia: when and what to do?
Current opinion in hematology 2011;18(2):111-6.
2011: DM Ross; Timothy P Hughes; J V Melo
Do we have to kill the last CML cell?
Leukemia 2011;25(2):193-200.
2010: Timothy P Hughes; Andreas Hochhaus; Susan Branford; Martin C Müller; Jaspal S Kaeda; Letizia Foroni; Brian J Druker; François Guilhot; Richard A Larson; Stephen G O'Brien; Marc S Rudoltz; Manisha Mone; Elisabeth Wehrle; Vijay Modur; John M Goldman; Jerald P Radich
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Blood 2010;116(19):3758-65.
2010: Deborah L White; V A Saunders; P Dang; J Engler; Timothy P Hughes
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
Leukemia 2010;24(11):1962-5.
2010: Susan Branford; Timothy P Hughes
Practical considerations for monitoring patients with chronic myeloid leukemia.
Seminars in hematology 2010;47(4):327-34.
2010: Stephen Fitter; Kate Vandyke; Christopher G Schultz; Deborah White; Timothy P Hughes; Andrew C W Zannettino
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
The Journal of clinical endocrinology and metabolism 2010;95(8):3763-7.
2010: D K Hiwase; D White; S Zrim; V Saunders; J V Melo; Timothy P Hughes
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Leukemia 2010;24(3):658-60.
2010: Kate Vandyke; Stephen Fitter; Andrea L Dewar; Timothy P Hughes; Andrew C W Zannettino
Dysregulation of bone remodeling by imatinib mesylate.
Blood 2010;115(4):766-74.
2009: David M Ross; Lisa Schafranek; Timothy P Hughes; Mario Nicola; Susan Branford; Joannah Score
Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification.
Cancer genetics and cytogenetics 2009;189(2):138-9.
2009: Timothy P Hughes; Susan Branford
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S266-71.
2008: Timothy P Hughes; Susan Branford; Deborah L White; John Reynolds; Rachel Koelmeyer; John F Seymour; Kerry Taylor; Chris Arthur; Anthony P Schwarer; James Morton; Julian Cooney; Michael F Leahy; Philip Rowlings; John Catalano; Mark Hertzberg; Robin Filshie; Anthony K Mills; Keith Fay; Simon Durrant; Henry Januszewicz; David Joske; Craig Underhill; Scott Dunkley; Kevin Lynch; Andrew Grigg
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Blood 2008;112(10):3965-73.
2008: DM Ross; Dale B Watkins; Timothy P Hughes; Susan Branford
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Clinical chemistry 2008;54(9):1568-71.
2008: DM Ross; Timothy P Hughes
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Leukemia & lymphoma 2008;49(7):1230-1.
2008: DM Ross; Timothy P Hughes
Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.
Pathology 2008;40(3):231-46.
2008: Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino
Long-term imatinib therapy promotes bone formation in CML patients.
Blood 2008;111(5):2538-47.
2007: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
The Journal of clinical investigation 2007;117(9):2562-9.
2007: Deborah L White; Verity A Saunders; Steven R Quinn; Paul W Manley; Timothy P Hughes
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.
Blood 2007;109(8):3609-10.
2007: Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
2006: Chi-hung Hui; Timothy P Hughes
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
Leukemia & lymphoma 2006;47(9):1721-3.
2006: Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Andrew C W Zannettino; Antony C Cambareri; Steven R Quinn; Paul W Manley; Timothy P Hughes
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
Blood 2006;108(2):697-704.
2006: Andrea L Dewar; Amanda N Farrugia; Mark R Condina; L Bik To; Timothy P Hughes; Barrie Vernon-Roberts; Andrew C W Zannettino
Imatinib as a potential antiresorptive therapy for bone disease.
Blood 2006;107(11):4334-7.
2006: DM Ross; Susan Branford; S Moore; Timothy P Hughes
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Leukemia 2006;20(4):664-70.
2005: Andrea L Dewar; Andrew C W Zannettino; Timothy P Hughes; A Bruce Lyons
Inhibition of c-fms by imatinib: expanding the spectrum of treatment.
Cell cycle (Georgetown, Tex.) 2005;4(7):851-3.
2005: Franziska Michor; Timothy P Hughes; Yoh Iwasa; Susan Branford; Neil P Shah; Charles L Sawyers; Martin A Nowak
Dynamics of chronic myeloid leukaemia.
Nature 2005;435(7046):1267-70.
2005: Andrea L Dewar; Antony C Cambareri; Andrew C W Zannettino; Bernadette L Miller; Kathleen V Doherty; Timothy P Hughes; A Bruce Lyons
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Blood 2005;105(8):3127-32.
2005: Andrea L Dewar; Kathleen V Doherty; Timothy P Hughes; A Bruce Lyons
Imatinib inhibits the functional capacity of cultured human monocytes.
Immunology and cell biology 2005;83(1):48-56.
2004: DM Ross; Timothy P Hughes
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
British journal of cancer 2004;90(1):12-9.
2003: Susan Branford; Zbigniew Rudzki; A Harper; Andrew Grigg; Kerry Taylor; Simon Durrant; Chris Arthur; Peter Browett; Anthony P Schwarer; D Ma; John F Seymour; Kenneth F Bradstock; David Joske; Kevin Lynch; Insa Gathmann; Timothy P Hughes
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Leukemia 2003;17(12):2401-9.
2003: Timothy P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
The New England journal of medicine 2003;349(15):1423-32.
2003: Chi-hung Hui; Timothy P Hughes
Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2003;1(9):538-45, 559.
2003: Andrea L Dewar; R M Domaschenz; Kathleen V Doherty; Timothy P Hughes; A Bruce Lyons
Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
Leukemia 2003;17(9):1713-21.
2003: Chi-hung Hui; K Y Goh; D White; Susan Branford; Andrew Grigg; John F Seymour; Yiu Lam Kwan; Sonya Walsh; R Hoyt; Annette Trickett; B Rudzki; D D F Ma; L Bik To; Timothy P Hughes
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Leukemia 2003;17(5):821-8.
2003: M M Roberts; PG Dyson; C Rawling; D Thorp; Trevor Rawling; D White; Noemi Horvath; Peter Bardy; Chi-hung Hui; G W Dart; L Bik To; Timothy P Hughes
Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Cytotherapy 2003;5(6):534-41.
2002: Susan Branford; Timothy P Hughes; Zbigniew Rudzki
Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene.
British journal of haematology 2002;117(4):875-7.
2002: Charles G Mullighan; Sue Heatley; Kathleen V Doherty; Ferenc Szabo; Andrew Grigg; Timothy P Hughes; Anthony P Schwarer; Jeff Szer; Brian D Tait; L Bik To; Peter Bardy
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.
Blood 2002;99(10):3524-9.
2002: Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Blood 2002;99(9):3472-5.
2000: S Moore; LA McDiarmid; Timothy P Hughes
Stem cell factor and chronic myeloid leukemia CD34+ cells.
Leukemia & lymphoma 2000;38(3-4):211-20.
2000: Susan Branford; Zbigniew Rudzki; Timothy P Hughes
A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia.
British journal of haematology 2000;109(3):635-7.
1999: Susan Branford; Timothy P Hughes; Zbigniew Rudzki
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
British journal of haematology 1999;107(3):587-99.
1998: S Moore; David N Haylock; Jean-Pierre Lévesque; LA McDiarmid; L M Samels; L Bik To; Paul J Simmons; Timothy P Hughes
Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Blood 1998;92(7):2461-70.
1998: ID Lewis; LA McDiarmid; L M Samels; L Bik To; Timothy P Hughes
Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells.
Blood 1998;91(2):630-40.
1997: PO Iversen; ID Lewis; S Turczynowicz; H Hasle; C Niemeyer; K Schmiegelow; S Bastiras; A Biondi; Timothy P Hughes; Angel F Lopez
Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice.
Blood 1997;90(12):4910-7.
1997: Deborah L White; C J Hutchins; S Turczynowicz; J Suttle; David N Haylock; Timothy P Hughes; CA Juttner; L Bik To
Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish.
Pathology 1997;29(3):289-93.
1997: ID Lewis; David N Haylock; S Moore; L Bik To; Timothy P Hughes
Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.
Leukemia 1997;11(4):581-7.
1997: Timothy P Hughes; Andrew Grigg; Jeff Szer; J Ho; D Ma; B M Dale; R M Green; J E Norman; RE Sage; Richard Herrmann; Paul Cannell; Anthony P Schwarer; Kerry Taylor; K Atkinson; Chris Arthur
Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.
British journal of haematology 1997;96(3):635-40.
1995: Sharad Kumar; Deborah L White; S Takai; S Turczynowicz; CA Juttner; Timothy P Hughes
Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms.
Human genetics 1995;95(6):641-4.
1995: Deborah L White; C J Hutchins; David N Haylock; S Turczynowicz; A Bishop; L Bik To; Timothy P Hughes; CA Juttner
Direct analysis of FACS-sorted hemopoietic cell fractions using FISH.
BioTechniques 1995;18(5):818, 820-1.